leukemia | Leukemia & Lymphoma Society | Leukemia | Chronic obstructive pulmonary disease | Acute lymphoblastic leukemia | Promyelocytic leukemia protein | chronic obstructive pulmonary disease | Chronic kidney disease | chronic kidney disease | Chronic fatigue syndrome | Acute myeloid leukemia | Suge Knight Represents: Chronic 2000 | Chronic traumatic encephalopathy | Chronic myelogenous leukemia | Chronic Kidney Disease | chronic fatigue syndrome | Chronic City | T-cell acute lymphoblastic leukemia | Feline leukemia virus | feline leukemia virus | Chronic toxicity | Chronic Town | Chronic Obstructive Pulmonary Disease (COPD) | Chronic Obstructive Pulmonary Disease | chronic myelogenous leukemia | Chronic mountain sickness | Chronic inflammatory demyelinating polyneuropathy | Chronic bacterial prostatitis | Chronic | Cancer and Leukemia Group B |
Tyrosine kinase inhibitors such as imatinib (marketed as Gleevec) have been developed to treat chronic myeloid leukemia (CML), in which the BCR-ABL fusion gene (the product of a reciprocal translocation between chromosome 9 and chromosome 22) is present in >95% of cases and produces hyperactivated abl-driven protein signaling.
In 2012 SETBP1 was identified as a novel oncogene in aCML; specific somatic mutations of this gene were discovered in patients affected by atypical Chronic Myeloid Leukemia (aCML) and related diseases.
At the 2010 annual meeting of the American Society of Hematology, ARIAD announced from a Phase I study of ponatinib in patients with resistant and refractory chronic myeloid leukemia (CML) and Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL).